Budget Amendment ID: FY2020-S3-575

EHS 575

Nasal Naloxone Coverage

Messrs. Cyr, Lesser, Welch and O'Connor and Ms. Gobi moved that the proposed new text be amended by adding the following seven sections:-

SECTION X. Chapter 32A of the General Laws is hereby amended by inserting after section 17Q the following section:- Section 17R. The group insurance commission and any carrier as defined in section 1 of chapter 176O or other entity which contracts with the commission to provide health benefits to eligible employees and retirees and their eligible dependents shall provide a separate payment for nasal naloxone dispensed or prescribed by a contracted healthcare provider in all settings, including but not limited to nasal naloxone provided in inpatient settings, emergency departments, outpatient settings, and community based clinics or health centers.

SECTION X. Chapter 118E of the General Laws, as so appearing, is hereby amended by inserting after section 10L the following section:- Section 10M. The division and its contracted health insurers, health plans, health maintenance organizations, behavioral health management firms and third party administrators under contract to a Medicaid managed care organization, the Medicaid primary care clinician plan, or an accountable care organization shall provide a separate payment for nasal naloxone dispensed or prescribed by a contracted healthcare provider in all settings, including but not limited to nasal naloxone provided in inpatient settings, emergency departments, outpatient settings, and community based clinics or health centers.

SECTION X. Chapter 175 of the General Laws, as so appearing, is hereby amended by inserting after section 47KK the following section:- Section 47LL. Any policy, contract, agreement, plan or certificate of insurance issued, delivered or renewed within the commonwealth, shall provide a separate payment for nasal naloxone dispensed or prescribed by a contracted healthcare provider in all settings, including but not limited to nasal naloxone provided in inpatient settings, emergency departments, outpatient settings, and community based clinics or health centers.

SECTION X. Chapter 176A of the General Laws, as so appearing, is hereby amended by inserting after section 8MM the following section:- Section 8NN. Any contract between a subscriber and the corporation under an individual or group hospital service plan which is delivered, issued or renewed within the commonwealth shall provide a separate payment for nasal naloxone dispensed or prescribed by a contracted healthcare provider in all settings, including but not limited to nasal naloxone provided in inpatient settings, emergency departments, outpatient settings, and community based clinics or health centers.

SECTION X. Chapter 176B of the General Laws, as so appearing, is hereby amended by inserting after section 4MM the following section:- Section 4NN. Any subscription certificate under an individual or group medical service agreement delivered, issued or renewed within the commonwealth shall provide a separate payment for nasal naloxone dispensed or prescribed by a contracted healthcare provider in all settings, including but not limited to nasal naloxone provided in inpatient settings, emergency departments, outpatient settings, and community based clinics or health centers. SECTION X. Chapter 176G of the General Laws, as so appearing, is hereby amended by inserting after section 4EE the following section:- Section 4FF. Any individual or group health maintenance contract that is issued or renewed shall provide a separate payment for nasal naloxone dispensed or prescribed by a contracted healthcare provider in all settings, including but not limited to nasal naloxone provided in inpatient settings, emergency departments, outpatient settings, and community based clinics or health centers.

SECTION X. Chapter 176I of the General Laws, as so appearing, is hereby amended by inserting after section 12 the following section:- Section 13. An organization entering into a preferred provider contract shall provide a separate payment for nasal naloxone dispensed or prescribed by a contracted healthcare provider in all settings, including but not limited to nasal naloxone provided in inpatient settings, emergency departments, outpatient settings, and community based clinics or health centers.